Arbutus Biopharma (ABUS) Stock Price, Financials & Analysis

Key Stats

Market Cap755.33 Mn

P/E4.94

FCF (Yr)-39.64 Mn

ROA (Yr)-30.21

EV to EBIT2.57

Net Income (Yr)-33.50 Mn

Enterprise Value382.30 Mn

Add ratio to table…

About

Arbutus Biopharma Corporation is a clinical stage biopharmaceutical company focused on infectious disease. It is developing imdusiran (AB-729) a GalNAc conjugated subcutaneously delivered RNAi therapeutic and an oral inhibitor of PD L1 for the treatment of chronic hepatitis B. The company also protects and defends its lipid nanoparticle technology which is used in certain mRNA vaccines and is involved in litigation to obtain compensation for unauthorized use of that…

Revenue is generated through licensing agreements royalty streams milestone payments and settlement proceeds. The company received an upfront cash payment of forty million dollars from Qilu Pharmaceutical Co Ltd for a license to develop and commercialize imdusiran in Greater China and Taiwan and is eligible for additional milestone payments up to two hundred forty five million dollars and double digit royalties on sales in that region. Arbutus receives tiered royalties on global net sales of Alnylam’s ONPATTRO product and a second royalty interest from Acuitas Therapeutics Inc. It also stands to receive a share of the noncontingent settlement payment of nine hundred fifty million dollars and a contingent payment up to one point three billion dollars from Moderna under a settlement agreement concerning lipid nanoparticle patent rights. Additionally the company holds an equity interest in Genevant Sciences Ltd and may benefit from future distributions.

Arbutus Biopharma Corporation operates in the competitive field of hepatitis B therapeutics where it faces large pharmaceutical companies such as GSK plc Gilead Sciences Inc Assembly Biosciences Inc Aligos Therapeutics Inc AusperBio Therapeutics Inc Brii Biosciences Limited Mirum Pharmaceuticals Inc and Precision Biosciences Inc. The company’s competitive advantage lies in its proprietary lipid nanoparticle platform its GalNAc conjugated RNAi therapeutic imdusiran and its oral PD L1 inhibitor which together target multiple steps of the hepatitis B virus life cycle. Its strong patent portfolio and ongoing litigation over lipid nanoparticle use provide additional leverage.

The company serves patients diagnosed with chronic hepatitis B and the healthcare providers that treat them. Its collaboration partners include Qilu Pharmaceutical Co Ltd Alnylam Pharmaceuticals Inc Acuitas Therapeutics Inc and Genevant Sciences Ltd. These relationships provide access to markets in Greater China Taiwan and global royalty streams.

How Arbutus Biopharma ranks

Ranked against the 671 companies in Pharmaceuticals and Biotechnology58 metrics · as of Nov 6, 2026

Valuation

12 metrics · Lower multiples rank higher; a negative multiple ranks last

P/E 4.71xMedian 17.8x 98^th
P/FCFNegative free cash flow −29.3xMedian 21.0x 78^th
P/Operating cash flowNegative operating cash flow −29.3xMedian 16.8x 78^th
P/S 3.97xMedian 8.14x 64^th
P/B 2.79xMedian 2.02x 39^th
P/Tangible book 2.79xMedian 2.24x 43^rd
EV/EBITDA 4.04xMedian 15.7x 99^th
EV/EBIT 4.22xMedian 20.9x 99^th
EV/Revenue 3.46xMedian 5.92x 61^st
EV/FCFNegative free cash flow −25.5xMedian 22.0x 73^rd
EV/Operating cash flowNegative operating cash flow −25.5xMedian 18.3x 72^nd
PEG (3Y EPS CAGR) 0.08Median 0.36 90^th

Growth

14 metrics · Year-on-year growth and three-year compound annual growth

Revenue growth (1Y) 1,079%Median 11.0% 96^th
Revenue CAGR (3Y) 97.6%Median 10.4% 87^th
Gross profit growth (1Y) —Median 11.8% No data —
Gross profit CAGR (3Y) —Median 12.3% No data —
Operating income growth (1Y) 350%Median −1.6% 99^th
Operating income CAGR (3Y) 58.2%Median 1.4% 95^th
Net income growth (1Y) 382%Median −3.3% 97^th
Net income CAGR (3Y) 60.0%Median −0.1% 93^rd
EPS growth (1Y) 375%Median 22.4% 97^th
EPS CAGR (3Y) 55.6%Median 25.9% 79^th
Operating cash flow growth (1Y) 59.1%Median −0.4% 89^th
Operating cash flow CAGR (3Y) 33.2%Median 2.1% 85^th
Free cash flow growth (1Y) 59.1%Median −0.1% 88^th
Free cash flow CAGR (3Y) 33.5%Median 2.5% 85^th

Profitability

14 metrics · Margins, returns on capital and the quality of earnings

Gross margin —Median 74.2% No data —
EBITDA margin 85.7%Median −214% 99^th
Operating margin 82.0%Median −213% 99^th
Pretax margin 83.9%Median −205% 99^th
Net margin 84.2%Median −196% 98^th
FCF margin −13.6%Median −181% 68^th
Operating cash flow margin −13.6%Median −175% 68^th
Return on equity 58.7%Median −54.7% 96^th
Return on assets 55.3%Median −41.1% 99^th
Return on invested capital —Median −5.3% No data —
Return on capital employed 54.7%Median −47.8% 99^th
Asset turnover 0.66xMedian 0.18x 82^nd
Cash conversion (OCF / net income) −0.16xMedian 1.14x 17^th
Stock comp / revenue 3.0%Median 29.2% 88^th

Financial Health

11 metrics · Leverage, liquidity and solvency; less debt ranks higher

Debt / assets —Median 20.0% No data —
Debt / equity —Median 0.27x No data —
Net debt / EBITDA —Median 1.22x No data —
Debt / FCF —Median 3.65x No data —
Liabilities / assets 5.6%Median 32.3% 94^th
Equity / assets 94.4%Median 67.7% 94^th
Interest coverage >1,000xMedian −10.0x 99^th
Current ratio 81.4xMedian 4.37x 99^th
Quick ratio 80.9xMedian 3.65x 99^th
Cash ratio 27.5xMedian 3.35x 97^th
Altman Z-score 25.7Median −0.80 94^th

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	LLY	ELI LILLY & Co	1,264.65 Bn	45.85	14.63	49.50 Bn
2	JNJ	Johnson & Johnson	677.74 Bn	42.11	6.82	44.65 Bn
3	ABBV	AbbVie Inc.	517.10 Bn	50.00	7.83	80.90 Bn
4	MRK	Merck & Co., Inc.	362.23 Bn	147.67	5.38	53.78 Bn
5	NVS	Novartis Ag	315.90 Bn	24.55	6.03	9.59 Bn
6	AZN	Astrazeneca Plc	289.40 Bn	33.26	5.34	32.35 Bn
7	AMGN	Amgen Inc	249.90 Bn	26.61	6.42	54.01 Bn
8	ABUS	Arbutus Biopharma Corp	0.76 Bn	4.94	4.16	-

S.No.

Ticker

Company

Market Cap

P/E

P/S

Total Debt (Qtr)

LLY

ELI LILLY & Co

1,264.65 Bn

45.85

14.63

49.50 Bn

JNJ

Johnson & Johnson

677.74 Bn

42.11

6.82

44.65 Bn

ABBV

AbbVie Inc.

517.10 Bn

50.00

7.83

80.90 Bn

MRK

Merck & Co., Inc.

362.23 Bn

147.67

5.38

53.78 Bn

NVS

Novartis Ag

315.90 Bn

24.55

6.03

9.59 Bn

AZN

Astrazeneca Plc

289.40 Bn

33.26

5.34

32.35 Bn

AMGN

Amgen Inc

249.90 Bn

26.61

6.42

54.01 Bn

ABUS

Arbutus Biopharma Corp

0.76 Bn

4.94

4.16

Arbutus Biopharma ABUS

About

Counterparty Name Breakdown of Revenue (2025)

Product and Service Breakdown of Revenue (2025)

How Arbutus Biopharma ranks

Valuation

Growth

Profitability

Financial Health

Shareholder Returns

Peer Comparison

Arbutus Biopharma ABUS

About

Counterparty Name Breakdown of Revenue (2025)

Product and Service Breakdown of Revenue (2025)

How Arbutus Biopharma ranks

Valuation

Growth

Profitability

Financial Health

Shareholder Returns

Peer Comparison

Create an account

Sign In

Reset Password